IRIS
CASSANITI, IRENE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.996
AS - Asia 2.346
EU - Europa 1.658
SA - Sud America 393
AF - Africa 140
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 2
Totale 7.540
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.875
SG - Singapore 670
CN - Cina 635
HK - Hong Kong 360
RU - Federazione Russa 337
VN - Vietnam 311
BR - Brasile 300
IT - Italia 291
DE - Germania 231
IE - Irlanda 225
FI - Finlandia 132
FR - Francia 130
GB - Regno Unito 102
ZA - Sudafrica 85
IN - India 78
CA - Canada 55
JP - Giappone 46
MX - Messico 43
PL - Polonia 38
BD - Bangladesh 36
ES - Italia 29
AR - Argentina 28
IQ - Iraq 28
NL - Olanda 28
TR - Turchia 28
PK - Pakistan 25
SE - Svezia 24
ID - Indonesia 20
VE - Venezuela 19
AT - Austria 17
PH - Filippine 16
CL - Cile 13
MA - Marocco 11
BE - Belgio 10
CH - Svizzera 9
CZ - Repubblica Ceca 9
LT - Lituania 9
SA - Arabia Saudita 9
TN - Tunisia 9
UA - Ucraina 9
UZ - Uzbekistan 9
CO - Colombia 8
EC - Ecuador 8
EG - Egitto 7
KE - Kenya 7
MY - Malesia 7
TH - Thailandia 7
IL - Israele 6
PY - Paraguay 6
AU - Australia 5
AZ - Azerbaigian 5
JM - Giamaica 5
KZ - Kazakistan 5
AE - Emirati Arabi Uniti 4
BO - Bolivia 4
CR - Costa Rica 4
ET - Etiopia 4
HR - Croazia 4
IR - Iran 4
JO - Giordania 4
LK - Sri Lanka 4
NP - Nepal 4
PE - Perù 4
DK - Danimarca 3
GR - Grecia 3
KG - Kirghizistan 3
KR - Corea 3
LV - Lettonia 3
MU - Mauritius 3
PA - Panama 3
RO - Romania 3
SN - Senegal 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
AM - Armenia 2
BH - Bahrain 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
GE - Georgia 2
LB - Libano 2
NI - Nicaragua 2
PS - Palestinian Territory 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
TT - Trinidad e Tobago 2
TZ - Tanzania 2
BA - Bosnia-Erzegovina 1
BZ - Belize 1
CG - Congo 1
CI - Costa d'Avorio 1
CM - Camerun 1
CU - Cuba 1
DM - Dominica 1
EE - Estonia 1
GT - Guatemala 1
GY - Guiana 1
HN - Honduras 1
HU - Ungheria 1
KH - Cambogia 1
KW - Kuwait 1
Totale 7.524
Salva come PNG Salva come JPEG
Città #
San Jose 443
Dallas 405
Singapore 399
Hong Kong 351
Ashburn 325
Beijing 207
Dublin 207
Chandler 175
New York 143
Munich 131
Ho Chi Minh City 106
Los Angeles 102
Boardman 98
Lauterbourg 92
Helsinki 83
Hanoi 75
Johannesburg 75
Shanghai 68
Milan 64
Redondo Beach 63
Moscow 54
Turku 49
Council Bluffs 41
Seattle 40
Tokyo 36
Orem 35
Pavia 35
Princeton 32
Warsaw 32
Buffalo 27
Lawrence 27
São Paulo 27
The Dalles 27
Frankfurt am Main 23
Denver 22
Medford 22
Santa Clara 20
London 19
Poplar 19
Toronto 19
Brooklyn 18
Atlanta 17
Montreal 17
Wilmington 17
Chennai 16
Da Nang 16
Boston 15
Chicago 15
Phoenix 15
Düsseldorf 14
Rome 14
Stockholm 14
Biên Hòa 13
Columbus 13
Mexico City 13
Amsterdam 12
Baghdad 12
San Francisco 12
Ankara 11
Houston 11
Lahore 11
Nuremberg 11
Washington 11
Falkenstein 10
Mumbai 10
Haiphong 9
Tashkent 9
Belo Horizonte 8
Charlotte 8
Lecce 8
Piscataway 8
Brussels 7
Guangzhou 7
Paris 7
Querétaro 7
Santiago 7
Hyderabad 6
Hải Dương 6
Jakarta 6
Jinan 6
Manchester 6
Marseille 6
Nairobi 6
Nanjing 6
Xi'an 6
Cairo 5
Casablanca 5
Curitiba 5
Ha Long 5
Medellín 5
Porto Alegre 5
Portsmouth 5
Pune 5
Salvador 5
Ann Arbor 4
Bangkok 4
Bergamo 4
Brasília 4
Bắc Giang 4
Caracas 4
Totale 4.764
Salva come PNG Salva come JPEG
Nome #
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study 148
Low risk for SARS-CoV2 symptomatic infection and early complications in paediatric patients during the ongoing CoVID19 epidemics in Lombardy 146
Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis 134
Low risk for SARS-CoV2 symptomatic infection and early complications in paediatric patients during the ongoing CoVID19 epidemics in Lombardy 131
EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count 125
Incidence of SARS-CoV-2 infection in health care workers from Northern Italy based on antibody status: immune protection from secondary infection- A retrospective observational case-controlled study 124
19n01, a Broadly Neutralizing Antibody Against Omicron BA.1, BA.2, BA.4/5, and Other SARS-CoV-2 Variants of Concern 121
Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up 118
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study 113
Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020 112
Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice 112
SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers 111
Impact of immunosuppressive treatment on the immunogenicity of mRNA Covid-19 vaccine in vulnerable patients with giant cell arteritis 109
Characterization of immune response against monkeypox virus in cohorts of infected patients, historic and newly vaccinated subjects 106
Characterization of varicella-zoster (Vzv) specific t cell response in healthy subjects and transplanted patients by using enzyme linked immunospot (elispot) assays 105
Human Cytomegalovirus-Specific Memory CD4+T-Cell Response and Its Correlation with Virus Transmission to the Fetus in Pregnant Women with Primary Infection 104
Differential Kinetics of Effector and Memory Responses Induced by Three Doses of SARS-CoV-2 mRNA Vaccine in a Cohort of Healthcare Workers 100
Dengue Virus-Specific Humoral and T Cellular Immune Response in Italian Residents and Travelers Returning from Endemic Areas 100
Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study 94
Detection of the SARS-CoV-2 in different biologic specimens from positive patients with COVID-19, in Northern Italy 91
Authors' response: COVID-19: how accurate are seroprevalence studies? 91
Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study 91
Macrophages and monocytes: “trojan horses” in covid-19 90
Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up 90
Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment 89
Sars-cov-2 virologic and immunologic correlates in patients with olfactory and taste disorders 88
CD4 T Cell Determinants in West Nile Virus Disease and Asymptomatic Infection 87
Immunological Aspects of Human Papilloma Virus-Related Cancers Always Says, "I Am like a Box of Complexity, You Never Know What You Are Gonna Get" 85
Evaluation of EBV- and HCMV-Specific T Cell Responses in Systemic Lupus Erythematosus (SLE) Patients Using a Normalized Enzyme-Linked Immunospot (ELISPOT) Assay 85
Immunity to SARS-CoV-2 up to 15 months after infection 84
Effect of a Third Dose of SARS-CoV-2 mRNA BNT162b2 Vaccine on Humoral and Cellular Responses and Serum Anti-HLA Antibodies in Kidney Transplant Recipients 84
Dynamics of humoral and cellular immunity elicited by the BNT162b2 mRNA vaccine in psoriatic patients under targeted immunosuppression: A longitudinal cohort study 83
Association between Vitamin D Serum Levels and Immune Response to the BNT162b2 Vaccine for SARS-CoV-2 83
Autoantibodies neutralizing type I IFNs underlie West Nile virus encephalitis in ∼40% of patients 83
EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count 81
Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection 81
Immunosuppressive treatments selectively affect the humoral and cellular response to SARS-CoV-2 in vaccinated patients with vasculitis 81
Machine Learning-based Voice Assessment for the Detection of Positive and Recovered COVID-19 Patients 81
Asymptomatic infection with clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) in carnivore pets, Italy, April 2023 80
The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy 80
Outbreak of measles genotype H1 in Northern Italy originated from a case imported from Southeast Asia, 2017 80
Adenovirus-vectored SARS-CoV-2 vaccine expressing S1-N fusion protein 80
Clinical, virological and immunological evolution of the olfactory and gustatory dysfunction in COVID-19 77
Conversion of monoclonal IgG to dimeric and secretory IgA restores neutralizing ability and prevents infection of Omicron lineages 77
ELISPOT assays with pp65 peptides or whole HCMV antigen are reliable predictors of immune control of HCMV infection in seropositive kidney transplant recipients 77
Adapting Neutralizing Antibodies to Viral Variants by Structure-Guided Affinity Maturation Using Phage Display Technology 76
Deep learning and machine learning-based voice analysis for the detection of COVID-19: A proposal and comparison of architectures 76
SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay 76
Performance of new pp65-IGRA for the quantification of HCMV-specific CD4+ T-cell response in healthy subjects and in solid organ transplant recipients 75
Performance of VivaDiag COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department 75
SARS-CoV-2 positivity in rectal swabs: implication for possible transmission 75
Human Cytomegalovirus and Epstein-Barr virus specific immunity in patients with ulcerative colitis 74
Infectious complications and immunotherapy: old pitfalls and new horizons 71
Immunological Aspects of Human Papilloma Virus-Related Cancers Always Says, “I Am like a Box of Complexity, You Never Know What You Are Gonna Get” 70
Human Cytomegalovirus (HCMV) - specific T-cell response after letermovir prophylaxis is predictive for subsequent HCMV reactivation in haematopoietic stem cell transplant recipients 70
Zika virus infection in pregnancy: Advanced diagnostic approaches in dengue-naive and dengue-experienced pregnant women and possible implication for cross-reactivity and cross-protection 70
Long-term dynamics of natural killer cells in response to SARS-CoV-2 vaccination: Persistently enhanced activity postvaccination 69
A single subcutaneous or intranasal immunization with adenovirus-based SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice 68
Evaluation of the Neutralizing Antibodies Response against 14 SARS-CoV-2 Variants in BNT162b2 Vaccinated Naïve and COVID-19 Positive Healthcare Workers from a Northern Italian Hospital 67
The 'hit-and-run' strategy and viral carcinogenesis 66
Human Cytomegalovirus Virion‐Associated mRNA as a Marker of Productive Infection in Immunocompromised Patients 66
Persistence of Immune Response Elicited by Three Doses of mRNA Vaccine against SARS-CoV-2 in a Cohort of Patients with Solid Tumors: A One-Year Follow-Up 66
Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern 65
Herpes zoster in patients with solid tumors treated with immune checkpoint inhibitors 65
Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs 65
Preliminary results on an autochthonous dengue outbreak in Lombardy Region, Italy, August 2023 64
Effectiveness of the available early therapies in reducing severe COVID-19 in non-hospitalized patients with solid tumors on active treatment 64
Characterization of CCP: Can We Use Past Convalescent Plasma from COVID-19 Patients for Treatment of New Emerging Variants? 63
Corrigendum to "Seroprevalence of SARS-CoV-2 in 1922 blood donors from the Lodi Red Zone and adjacent Lodi metropolitan and suburban area" [Clin Microbiol Infect 27 (6) (2021 Jun) 914.e1-914.e4] 63
Both SARS-CoV-2 infection and vaccination in pregnancy elicited neutralizing antibodies in pregnant women and newborns 63
mRNA BNT162b Vaccine Elicited Higher Antibody and CD4+ T-Cell Responses than Patients with Mild COVID-19 63
Auto-Abs neutralizing type I IFNs in patients with severe Powassan, Usutu, or Ross River virus disease 62
Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant 62
Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection 62
Seroprevalence of SARS-CoV-2 in blood donors from the Lodi Red Zone and adjacent Lodi metropolitan and suburban area 62
Immune Control of Human Cytomegalovirus (HCMV) Infection in HCMV-Seropositive Solid Organ Transplant Recipients: The Predictive Role of Different Immunological Assays 61
The 2023 dengue outbreak in Lombardy, Italy: A one-health perspective 60
High-throughput peptide array analysis and computational techniques for serological profiling of flavivirus infections: Implications for diagnostics and vaccine development 58
Serum and breastmilk SARS-CoV-2 specific antibodies following BNT162b2 vaccine: prolonged protection from SARS-CoV-2 in newborns and older children 58
Emergence of Letermovir-resistant HCMV UL56 mutant during rescue treatment in a liver transplant recipient with ganciclovir-resistant infection HCMV: a case report 56
Vaccination for seasonal influenza, pneumococcal infection and SARS-CoV-2 in patients with solid tumors: recommendations of the Associazione Italiana di Oncologia Medica (AIOM) 56
SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice 55
Severe acute respiratory syndrome coronavirus 2 RNA contamination of inanimate surfaces and virus viability in a health care emergency unit 55
Severe acute respiratory syndrome coronavirus 2 RNA contamination of inanimate surfaces and virus viability in a health care emergency unit 55
West nile or usutu virus? A three-year follow-up of humoral and cellular response in a group of asymptomatic blood donors 54
Immune response to bnt162b2 in solid organ transplant recipients: Negative impact of mycophenolate and high responsiveness of sars-cov-2 recovered subjects against delta variant 54
Photopheresis abates the anti-hla antibody titer and renal failure progression in chronic antibody-mediated rejection 53
SARS-CoV-2 variants inactivation of plasma units using a riboflavin and ultraviolet light-based photochemical treatment 52
Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19 52
Molecular Epidemiology of Rhinovirus/Enterovirus and Their Role on Cause Severe and Prolonged Infection in Hospitalized Patients 49
Memory T cells specific for HBV enumerated by a peptide-based cultured enzyme-linked immunospot assay in healthy HBV-vaccinated subjects 49
Performance of Whole Blood Stimulation Assays for the Quantification of SARS-CoV-2 Specific T-Cell Response: A Cross-Sectional Study 46
Development of hepatitis triggered by SARS-CoV-2 vaccination in patient with cancer during immunotherapy: a case report 42
Vaccination for herpes zoster in patients with solid tumors: a position paper on the behalf of the Associazione Italiana di Oncologia Medica (AIOM) 42
SARS-CoV-2 viability on different surfaces after gaseous ozone treatment: a preliminary evaluation 38
null 37
Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant 34
Thirteen Years of Phleboviruses Circulation in Lombardy, a Northern Italy Region 32
Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection 25
Tetravalent SARS-CoV-2 S1 subunit protein vaccination elicits robust humoral and cellular immune responses in SIV-infected rhesus macaque controllers 24
Totale 7.622
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.432
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.432
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213 0 0 0 0 0 0 0 0 0 0 3 0
2021/2022184 2 1 5 26 12 3 4 13 4 17 16 81
2022/2023618 42 51 4 48 31 38 6 17 278 12 79 12
2023/2024664 61 113 40 31 53 161 57 45 6 22 39 36
2024/20251.919 49 95 29 104 35 125 114 77 489 127 236 439
2025/20264.210 361 291 515 514 514 196 864 280 421 254 0 0
Totale 7.678